ASCO 2023: Highlights and analysis

ASCO 2023: Latest in PARP inhibitors in prostate cancer

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC

Extended lymph node removal does not benefit patients with clinically localised muscle-invasive bladder cancer

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses in multiple tumour types

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity

AI-derived digital pathology-based biomarker predicts benefit of long-term ADT with RT in localised high-risk prostate cancer

Tackling low-volumes of clinical trials in Africa

Looking into the future diagnosis and treatment options for prostate cancer in Africa

Management of prostate cancer in Africa: Looking to the future

The HypoAfrica study and AC3T research partnerships at NLCC

Achieving health equity in cancer care in the Philippines